Syntheses and antitumor activity of cis-restricted combretastatins: 5- membered heterocyclic analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 22, 1998, Pages 3153-3158

  Ohsumi, Koji ^a   Hatanaka, Toshihiro ^a   Fujita, Koichi ^a   Nakagawa, Ryusuke ^a   Fukuda, Yumiko ^a   Nihei, Yukio ^a   Suga, Yasuyo ^a   Morinaga, Yoshihiro ^a   Akiyama, Yukio ^a   Tsuji, Takashi ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AC 7739; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN DERIVATIVE; HETEROCYCLIC COMPOUND; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CATTLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SOLUBILITY; DRUG SYNTHESIS; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN;

ANIMALIA; BOS TAURUS; MURINAE;

EID: 0032542045     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00579-4     Document Type: Article

References (22)

1. 1. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Experientia 1989, 45, 209. Hamel, E.; Lin, C. M. Biochem. Pharmacol. 1983, 32, 3864. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Biochemistry 1989, 28, 6984.
2. 1. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Experientia 1989, 45, 209. Hamel, E.; Lin, C. M. Biochem. Pharmacol. 1983, 32, 3864. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Biochemistry 1989, 28, 6984.
3. 1. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Experientia 1989, 45, 209. Hamel, E.; Lin, C. M. Biochem. Pharmacol. 1983, 32, 3864. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Biochemistry 1989, 28, 6984.
4. 1. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Experientia 1989, 45, 209. Hamel, E.; Lin, C. M. Biochem. Pharmacol. 1983, 32, 3864. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Biochemistry 1989, 28, 6984.
5. 2. McGown, A. T.; Fox, B. W. Cancer Chemother. Pharmacol. 1990, 26, 79. El-Zayat, A. A. E.; Degen, D.; Drabek, S.; Clark, G. M.; Pettit, G. R.; Von Hoff, D. D. Anti-Cancer Drugs 1993, 4, 19.
6. 2. McGown, A. T.; Fox, B. W. Cancer Chemother. Pharmacol. 1990, 26, 79. El-Zayat, A. A. E.; Degen, D.; Drabek, S.; Clark, G. M.; Pettit, G. R.; Von Hoff, D. D. Anti-Cancer Drugs 1993, 4, 19.
7. 3. Pettit, G. R.; Temple, C. Jr.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Anti-Cancer Drug Des. 1995, 10, 299.
8. 4. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. J. Med. Chem. 1998, 41, 3022.
9. 5. Nihei, Y.; Suga, Y.; Morinaga, Y.; Ohishi, K.; Suzuki, M.; Okano, A.; Ohsumi, K.; Nakagawa, R.; Tsuji, T.; Akiyama, Y.; Tsuruo. Proceedings of the American Association for Cancer Research, 39, # 1143, 1998. Nihei, Y.; Suzuki, M.; Okano, A.; Tsuji, T.; Akiyama, Y.; Saito, S.; Hori, K.; Sato, Y. Proceedings of the American Association for Cancer Research, 39, # 324, 1998.
10. 5. Nihei, Y.; Suga, Y.; Morinaga, Y.; Ohishi, K.; Suzuki, M.; Okano, A.; Ohsumi, K.; Nakagawa, R.; Tsuji, T.; Akiyama, Y.; Tsuruo. Proceedings of the American Association for Cancer Research, 39, # 1143, 1998. Nihei, Y.; Suzuki, M.; Okano, A.; Tsuji, T.; Akiyama, Y.; Saito, S.; Hori, K.; Sato, Y. Proceedings of the American Association for Cancer Research, 39, # 324, 1998.
11. 6. McGown, A. T.; Fox, B. W. Anti-Cancer Drug Des. 1989, 3, 249.
12. 7. Superimposition was calculated by Molecular Modeling System SYBYL, Version 6.2; Tripos Associates, Inc.
13. 8. Since we started this study, the synthesis of structure-restricted combretastatin analogues was reported. Shirai, R.; Okabe, T.; Iwasaki, S. Heterocycles 1997, 46, 1457.
14. 9. Aoyama, T.; Inoue, S.; Shioiri, T. Tetrahedron Lett. 1984, 25, 433.
15. 10. Ife, R. J.; Leach, C. A.; Pope, A. J.; Theobald, C. J. Bioorg. Med. Chem. Lett., 1995, 5, 543.
16. 11. Meguro, K.; Kuwada, Y. Chem. Pharm. Bull. 1973, 21, 2375. Fray, M. J.; Bull, D. J.; Cooper, K.; Parry, M. J.; Stefaniak, M. H. J. Med. Chem. 1995, 38, 3524.
17. 11. Meguro, K.; Kuwada, Y. Chem. Pharm. Bull. 1973, 21, 2375. Fray, M. J.; Bull, D. J.; Cooper, K.; Parry, M. J.; Stefaniak, M. H. J. Med. Chem. 1995, 38, 3524.
18. 12. Hamel, E.; Lin, C. M. Biochemistry 1984, 23, 4173. Muzaffar, A.; Brossi, A.; Lin, C. M.; Hamel, E. J. Med. Chem. 1990, 33, 567.
19. 12. Hamel, E.; Lin, C. M. Biochemistry 1984, 23, 4173. Muzaffar, A.; Brossi, A.; Lin, C. M.; Hamel, E. J. Med. Chem. 1990, 33, 567.
20. 13. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Cancer Res. 1988, 48, 589. Mossman, T. J. Immunol. Meth. 1983, 65, 55.
21. 13. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Cancer Res. 1988, 48, 589. Mossman, T. J. Immunol. Meth. 1983, 65, 55.
22. 14. Fragments of colon 26 tumor (5mg) were inoculated sc into CD2F1 mice. Test compounds were given iv or sc on days 7, 11 and 15. On day 21, the tumor weights were measured. The inhibition ratio was evaluated as (1-T/C)X100 (%) (T; the mean tumor weight of the treated group, C; the mean tumor weight of the control group). Each group consisted of 5 mice.